scispace - formally typeset
Journal ArticleDOI

Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials.

Matteo Monami, +2 more
- 01 Oct 2013 - 
- Vol. 15, Iss: 10, pp 938-953
Reads0
Chats0
TLDR
Cardiovascular safety of sulfonylurea has been questioned by some authors and all available data on this issue from randomized trials is collected.
Abstract
Aim Cardiovascular safety of sulfonylurea has been questioned by some authors. This article aims at collecting all available data on this issue from randomized trials. Methods A meta-analysis was performed including all trials with a duration of at least 6 months, comparing a sulfonylurea with a non-sulfonylurea agent in type 2 diabetes. Major cardiovascular events (MACE) and mortality were retrieved and combined to calculate Mantel-Haenzel odds ratio (MH-OR). Results Of the 115 selected trials, 62 reported information on MACE, and 30 reported at least one event. MH-OR for sulfonylurea was 1.08 [0.86–1.36], p = 0.52 (1.85 [1.20–2.87], p = 0.005, in the five trials vs. DPP4 inhibitors, no significant differences vs. other comparators). The MH-OR for myocardial infarction and stroke was 0.88 [0.75–1.04], p = 0.13 and 1.28 [1.03–1.60], p = 0.026, respectively. Mortality was significantly increased with sulfonylureas (MH-OR: 1.22 [1.01–1.49], p = 0.047). Conclusions In type 2 diabetes, the use of sulfonylureas is associated with increased mortality and a higher risk of stroke, whereas the overall incidence of MACE appears to be unaffected. Significant differences in cardiovascular risk could be present in direct comparisons with specific classes of glucose-lowering agents, such as DPP4 inhibitors, but this hypothesis needs to be confirmed in long-term cardiovascular outcomes trials. The results of this meta-analysis need to be interpreted with caution, mainly because of limitations in trial quality and under-reporting of information on cardiovascular events and mortality. However, the cardiovascular safety of sulfonylureas cannot be considered established unless it is evaluated in long-term cardiovascular outcomes trials.

read more

Citations
More filters
Journal ArticleDOI

Certain sulfonylurea drugs increase serum free fatty acid in diabetic patients: A systematic review and meta-analysis

TL;DR: It is found that SU treatment combined with other antidiabetics could also increase the concentration of serum FFA, and the fundamental underlying mechanism still needs further investigation.
Journal ArticleDOI

[Diagnosis, Prevention and Treatment of Cardiovascular Disease in People with Diabetes and Prediabetes].

TL;DR: In this paper, the authors provide guidance on diagnosis, treatment and choice of therapy for individuals with type 2 diabetes without and with concomitant or secondary cardiovascular disease, including heart failure, atrial fibrillation, coronary heart disease and sudden cardiac death.
Journal ArticleDOI

Hyperglycemia, hypoglycemia and glycemic variability in the elderly: a fatal triad?

Matteo Monami, +1 more
TL;DR: Books are reviewed supporting the hypothesis that hyperglycemia, hypoglycaemia and glycemic variability are a fatal triad capable of increasing morbidity and mortality in patients with diabetes mellitus and an adequate glycemic control, in particular in elderly patients, should be achieved.
Journal ArticleDOI

Safety of diabetes drugs in patients with heart failure.

TL;DR: A review of the available evidence on the safety of diabetes drugs in HF, focused on the main observational and experimental studies, helps understand the neutrality, risks and potential benefits of these agents.
Journal ArticleDOI

[Combination of oral antidiabetic drugs: What fits together?]

TL;DR: Bei der Behandlung des Typ-2-Diabetes kann der Arzt heute auf verschiedene Substanzklassen zurückgreifen und über Konsequenzen für die individualisierte Therapie informiert der folgende Beitrag.
References
More filters
Journal ArticleDOI

Bias in meta-analysis detected by a simple, graphical test

TL;DR: Funnel plots, plots of the trials' effect estimates against sample size, are skewed and asymmetrical in the presence of publication bias and other biases Funnel plot asymmetry, measured by regression analysis, predicts discordance of results when meta-analyses are compared with single large trials.
Journal ArticleDOI

Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement

TL;DR: A structured summary is provided including, as applicable, background, objectives, data sources, study eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, conclusions and implications of key findings.
Journal ArticleDOI

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

TL;DR: PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) is introduced, an update of the QUOROM guidelines for reporting systematic reviews and meta-analyses.
Journal Article

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

R C Turner, +398 more
- 12 Sep 1998 - 
TL;DR: In this article, the effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared.
Journal ArticleDOI

Assessing the quality of reports of randomized clinical trials : is blinding necessary?

TL;DR: An instrument to assess the quality of reports of randomized clinical trials (RCTs) in pain research is described and its use to determine the effect of rater blinding on the assessments of quality is described.
Related Papers (5)

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

R C Turner, +398 more
- 12 Sep 1998 -